Product information and disease description
Place of product in therapy
88 evidence topics · 31 sources
Lytenava (bevacizumab-vikg)
Neovascular age-related macular degeneration
- Manufacturer
- Outlook Therapeutics
- Regulatory submission
- BLA approved July 2026
- Last updated